



## Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

November 24, 2021

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4<sup>th</sup> Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of the company's participation are as follows:

- **4<sup>th</sup> Annual Evercore ISI HealthCONx Conference**

Conference Date: November 30 – December 2, 2021

Fireside Chat Time/Date: 11:45 a.m. Eastern on Thursday, December 2, 2021

Format: Virtual conference; webcast available

To access the live webcast of the fireside chat, please visit the "Events & Presentations" page of Revolution Medicines' website at <https://ir.revmed.com/events-and-presentations>. Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

### **About Revolution Medicines, Inc.**

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 [sdiaz@vidasp.com](mailto:sdiaz@vidasp.com) For Media: Vida Strategic Partners Tim Brons 415-675-7402 [tbrons@vidasp.com](mailto:tbrons@vidasp.com)